Targeting STAT3 Enzyme for Cancer Treatment

被引:0
|
作者
Arun, Sowmiya [1 ]
Patel, Praveen Kumar [1 ]
Lakshmanan, Kaviarasan [2 ]
Rajangopal, Kalirajan [1 ]
Swaminathan, Gomathi [1 ]
Byran, Gowramma [1 ]
机构
[1] JSS Acad Higher Educ & Res, Dept Pharmaceut Chem, JSS Coll Pharm, Nilgiris 643001, Tamil Nadu, India
[2] Satyabhama Inst Sci & Technol, Sch Pharm, Dept Pharmaceut Chem, Chennai, Tamil Nadu, India
关键词
STAT3; inhibitors; SH-2; domain; proliferation; phosphorylation; hematological malignancies; tyrosine residue; NF-KAPPA-B; SIGNAL TRANSDUCER; TRANSCRIPTION; 3; KEY REGULATOR; EXPRESSION; ACTIVATOR; COMMUNICATION; SUPPRESSOR; APOPTOSIS; REVEALS;
D O I
10.2174/0113895575254012231024062619
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A category of cytoplasmic transcription factors called STATs mediates intracellular signaling, which is frequently generated at receptors on cell surfaces and subsequently sent to the nucleus. STAT3 is a member of a responsible for a variety of human tumor forms, including lymphomas, hematological malignancies, leukemias, multiple myeloma and several solid tumor types. Numerous investigations have demonstrated constitutive STAT3 activation lead to cancer development such as breast, head and neck, lung, colorectal, ovarian, gastric, hepatocellular, and prostate cancers. It's possible to get a hold of the book here. Tumor cells undergo apoptosis when STAT3 activation is suppressed. This review highlights the STAT3 activation and inhibition which can be used for further studies.
引用
收藏
页码:1252 / 1261
页数:10
相关论文
共 50 条
  • [11] Targeting STAT3 in Cancer with Nucleotide Therapeutics
    Lau, Yue-Ting K.
    Ramaiyer, Malini
    Johnson, Daniel E.
    Grandis, Jennifer R.
    CANCERS, 2019, 11 (11)
  • [12] Targeting the STAT3 pathway with STAT3 degraders
    Wang, Zhijie
    Liao, Xiaotong
    He, Haiqi
    Guo, Xia
    Chen, Jianjun
    TRENDS IN PHARMACOLOGICAL SCIENCES, 2024, 45 (09) : 811 - 823
  • [13] Development of STAT3 dual-targeting strategies for the treatment of pancreatic cancer
    Fishel, Melissa L.
    Grimard, Michelle L.
    Kelley, Mark R.
    Rosa, David A.
    Shouksmith, Andrew
    Tin, Gary
    Park, Ji
    Gunning, Patrick T.
    CANCER RESEARCH, 2016, 76
  • [14] Targeting Wnt5a and STAT3 pathways for the treatment of prostate cancer
    Canesin, Giacomo
    Evans-Axelsson, Susan
    Hellsten, Rebecka
    Don-Doncow, Nicholas
    Andersson, Tommy
    Bjartell, Anders
    CANCER RESEARCH, 2015, 75
  • [15] Novel STAT3 inhibitors targeting the STAT3 dimerization
    Hua, Yaping
    Azeem, Waqas
    Oyan, Anne Margrete
    Kalland, Karl-Henning
    CANCER RESEARCH, 2022, 82 (12)
  • [16] Direct Targeting Options for STAT3 and STAT5 in Cancer
    Orlova, Anna
    Wagner, Christina
    de Araujo, Elvin D.
    Bajusz, David
    Neubauer, Heidi A.
    Herling, Marco
    Gunning, Patrick T.
    Keseru, Gyorgy M.
    Moriggl, Richard
    CANCERS, 2019, 11 (12)
  • [17] TARGETING STAT3 FOR THE TREATMENT OF PROLIFERATIVE DIABETIC RETINOPATHY
    Hombrebueno, J. R.
    Lynch, A.
    Obasanmi, G.
    Chen, M.
    Heping, X.
    EUROPEAN JOURNAL OF OPHTHALMOLOGY, 2016, 26 (04) : E93 - E93
  • [18] Targeting STAT3 Signaling Pathway in Colorectal Cancer
    Gargalionis, Antonios N.
    Papavassiliou, Kostas A.
    Papavassiliou, Athanasios G.
    BIOMEDICINES, 2021, 9 (08)
  • [19] Targeting STAT3 with silibinin to improve cancer therapeutics
    Bosch-Barrera, Joaquim
    Queralt, Bernardo
    Menendez, Javier A.
    CANCER TREATMENT REVIEWS, 2017, 58 : 61 - 69
  • [20] Targeting STAT3 in cancer: how successful are we?
    Yue, Pedbin
    Turkson, James
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2009, 18 (01) : 45 - 56